There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on OrthoPediatrics (KIDS – Research Report) and Enanta Pharmaceuticals (ENTA – Research Report) with bullish sentiments.
Enanta Pharmaceuticals (ENTA)
In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Enanta Pharmaceuticals, with a price target of $22.00. The company’s shares closed last Monday at $14.60.
According to TipRanks.com, Buchanan has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Enanta Pharmaceuticals is a Hold with an average price target of $19.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KIDS:
- KIDS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- OrthoPediatrics Corp. to Report First Quarter 2024 Financial Results on May 7, 2024
- OrthoPediatrics Corp. to Highlight its Pediatric Scoliosis Solutions at 8th Annual International Children’s Spine Symposium (ICSS)
- OrthoPediatrics Corp. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- OrthoPediatrics files $250M mixed securities shelf
